Stem cells therapies are currently used in bone marrow transplants that are used to treat leukemia, and scientists believe in the future, they can be used to treat cancer, Parkinson’s disease, and multiple sclerosis. Researchers at the at the University of Cambridge have developed a way of producing stem cells with blood. The research was published in the Stem Cells: Translational Medicine journal. With all the controversy about embryonic stem cells, scientists are looking for alternative sources, such a teeth and umbilical cord blood.
Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.
Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $18.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 85 and a forward PE of 42.6. Earnings for the latest quarter were up an incredible 40.6%% on a 44.2% boost in revenues.
Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 33 times current earnings, and 12 times forward earnings. However, earnings for the latest quarter were up a strong 17.5% on a 3.9% rise in sales.
Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company’s main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 22 and a forward PE of 14. Quarterly earnings were up 13.7%% on a 13.6%% revenue increase.
For a free list of twenty stocks involved in stem cell research, along with some cord blood stocks, which you can download, sort, and update, go to WallStreetNewsNetwork.com.
Disclosure: Author did not own any of the above at the time the article was written.